Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy (Q38400338)

3 July 2019

title

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy (English)

1 reference

3 July 2019

main subject

anti-retroviral agent

0 references

1 reference

10

Jean K Carr

1 reference

3 July 2019

Nicaise Ndembi

8

object named as

Nicaise Ndembi

1 reference

3 July 2019

author name string

Mary-Ann A Etiebet

1

1 reference

3 July 2019

James Shepherd

2

1 reference

3 July 2019

Rebecca G Nowak

3

1 reference

3 July 2019

Man Charurat

4

1 reference

3 July 2019

Harry Chang

5

1 reference

3 July 2019

Samuel Ajayi

6

1 reference

3 July 2019

Olufunmilayo Elegba

7

1 reference

3 July 2019

Alashle Abimiku

9

1 reference

3 July 2019

Lindsay M Eyzaguirre

11

1 reference

3 July 2019

William A Blattner

12

1 reference

3 July 2019

language of work or name

English

0 references

publication date

1 February 2013

1 reference

3 July 2019

published in

AIDS

1 reference

3 July 2019

volume

27

1 reference

3 July 2019

issue

4

1 reference

3 July 2019

page(s)

553-561

1 reference

3 July 2019

Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution

cites work

1 reference

12 December 2020

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

1 reference

12 December 2020

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates

1 reference

12 December 2020

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

1 reference

12 December 2020

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients

1 reference

12 December 2020

K65R, TAMs and tenofovir.

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

Resistance issues with new nucleoside/nucleotide backbone options

1 reference

12 December 2020

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations

1 reference

12 December 2020

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

1 reference

12 December 2020

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent

1 reference

12 December 2020

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

1 reference

12 December 2020

Frequency and Treatment‐Related Predictors of Thymidine‐Analogue Mutation Patterns in HIV‐1 Isolates after Unsuccessful Antiretroviral Therapy

1 reference

12 December 2020

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.

1 reference

12 December 2020

Web resources for HIV type 1 genotypic-resistance test interpretation

1 reference

12 December 2020

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level

1 reference

12 December 2020

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine

1 reference

12 December 2020

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

12 December 2020

First molecular surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-Mexico border

1 reference

12 December 2020

Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya

1 reference

12 December 2020

The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa

1 reference

12 December 2020

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon

1 reference

12 December 2020

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières

1 reference

12 December 2020

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

1 reference

12 December 2020

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings

1 reference

12 December 2020

Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)

1 reference

12 December 2020

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

1 reference

12 December 2020

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria

1 reference

12 December 2020

Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens

1 reference

12 December 2020

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir

1 reference

12 December 2020

International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase

1 reference

12 December 2020

The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

1 reference

12 December 2020

HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil

1 reference

12 December 2020

Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring

1 reference

12 December 2020

Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy

1 reference

12 December 2020

A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1

1 reference

12 December 2020

Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.

1 reference

12 December 2020

2011 update of the drug resistance mutations in HIV-1.

1 reference

12 December 2020

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

1 reference

12 December 2020

The neighbor-joining method: a new method for reconstructing phylogenetic trees

1 reference

12 December 2020

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

1 reference

12 December 2020

The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro

1 reference

12 December 2020

Subgroup G HIV type 1 isolates from Nigeria

1 reference

12 December 2020

Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination

1 reference

12 December 2020

Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria

1 reference

12 December 2020

10.1097/QAD.0B013E32835B0F59

Identifiers

DOI

1 reference

3 July 2019

PMC publication ID

6519052

1 reference

3 July 2019

PubMed publication ID

23079810

1 reference

3 July 2019